1Raij L. Recommendation for the management of special populations. renal disease in diabetes. Am J Hypertens,2003,16(11 Pt 2):46 - 49.
2Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabetic Medicine, 2001,18(3) :185 - 192.
3Friedman EA. Advanced glycosylated end - products and hyperglycaemia in the pathogenesis of diabetic complications. Diabetes Care, 1999,22 ( Suppl 2):1365 - 1371.
4Schmidt AM, Yan SD, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands.Biochim Biophys Acta,2000,1498(2 - 3) :99 - 111.
5Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci,2002,59(7) .1117 - 1128.
6Wendt T,Tanji N, Guo J,et al. Glucose,glycation and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol,2003,14:1383- 1395.
7Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes - associated sustained activation of the transcription factor nuclear factor kappa B. Diabetes, 2001,50:2792 - 2808.
8Sakaguchi T, Sousa M, Yan SD, et al. Restenosis: central role of RAGE - dependent neointimal expansion. Circulation, 2001,104(Suppl) : Ⅱ - 522.
9Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E- null mice. Arterioscler Thromb,2001,21:905 - 910.
10Twigg SM,Chen MM,Joly AH, et al. Advanced glycosylation end products up - regulate connective tissue growth factor (insulin- like growth factor- binding protein- related protein 2) in expansion of extracellular matrix in diabetes mellitus. Endocrinology, 2001,142 : 1760 - 1769.
二级参考文献29
1[1]Neeper M, Schmidt AM, Brett J, et al.Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of protein. J Biol Chem, 1992, 267:14998～15004.
2[2]Schmidt AM, Yan SD, Yan SF, et al.The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta, 2000, 1498:99～111.
3[3]Yeh CH, Sturgis L, Haidacher J, et al.Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes, 2001, 50: 1495～1504.
4[4]Vlassara H, Bucala R, Striker L, et al.Pathogenic effects of advanced glycosylation:biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest, 1994, 70: 138～151.
5[5]Hou FF, Reddan DN, Seng WK, et al. Pathogenesis of β2-microglobulin amyloidosis: role of monocytes/macrophages. Semin Dial. 2001, 14: 135～139.
6[6]Sun M, Muinehiro Y, Toshiyuki I, et al.Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Path, 1998, 79: 207～222.
7[7]Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol, 2002, 13: 1296～1306.
8[8]Higashi T, Sano H, Saishoji T, et al.The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes, 1997, 46: 463～472.
9[9]Hou FF, Miyata T, Boyce J, et al. β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001, 59: 990～1002.
10[1]Viberti GC. Why do we have to invoke genetic susceptibility for diabetic nephropathy [J]? Kidney Int, 1999,55: 2526 - 2527.
